Psoriasis: Which therapy for which patient, updated, part II. Focus on special populations and chronic infections. (PubMed, J Am Acad Dermatol) - Oct 26, 2026 - "Traditional agents remain useful in selected scenarios, while IL-17, IL-23, IL-36, TNF-α, TYK2, JAK, and other targeted therapies offer expanding options. Available evidence is summarized with expert-opinion recommendations where comparative data are limited."
Journal • Review • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Pediatrics • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Pustular Psoriasis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Tuberculosis • IL17A • IL23A • TNFA • TYK2
|
|
Anusha Pasumarthi; Kateryna Karpoff; Mark Lebwohl
|